News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Full results and Plain Language Summary for CheckMate 77T trial – NEJM
Photo of NEJM from tukuz.com
May 28, 2024, 07:48

Full results and Plain Language Summary for CheckMate 77T trial – NEJM

NEJM shared on X/Twitter:

“In the CheckMate 77T trial, researchers assessed whether adding adjuvant nivolumab to neoadjuvant nivolumab plus chemotherapy would improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Full results and Plain Language Summary.”

Perioperative Nivolumab in Resectable Lung Cancer A PLAIN LANGUAGE SUMMARY Top Figure: Illustration of treatment options during the Neoadjuvant and Adjuvant Periods. Bottom Figure: Graph of the Percentage of Patients with Event-free Survival

Source: NEJM/X

adjuvant nivolumab cancer CheckMate 77T trial NEJM neoadjuvant nivolumab OncoDaily Oncology resectable NSCLC
Special Coverage
Insight
Dec 19, 2024, 08:27
What role does mentorship play in building resilience? - ESMO
Blog
Dec 19, 2024, 08:16
The U.S. House of Representatives released text of the FY25 Continuing Resolution - ACS CAN
Insight
Dec 19, 2024, 08:12
Talha Badar: ASH24 abstract in acute leukemia and MDS
Blog
Dec 19, 2024, 08:08
T790M resistance mutations in EGFR+ lung cancer - EGFR Positive Lung Cancer UK
Positive
Dec 19, 2024, 08:03
Eric K. Singhi: Honored to be recognized as this year’s Emerging Leader by MUSC Alamni
Blog
Dec 19, 2024, 07:57
Marilyn Bui: Moffitt Cancer Center achieved the highest patient satisfaction score this year
Blog
Dec 19, 2024, 07:51
Laura Bukavina: The use of TMT for localized bladder cancer in octogenarians
Opinion
Dec 19, 2024, 07:45
Gustavo Viani: Stereotactic Body Radiation Therapy - Does scheduling matter?
Blog
Dec 19, 2024, 07:41
IMPACT Malignant Hematology Webinar on the evolving treatment landscape of lower-risk MDS - Vanderbilt-Ingram Cancer Center
Societies
Dec 19, 2024, 07:38
ASCOGI25 abstract titles are now available
Insight
Dec 19, 2024, 07:27
Geoffrey Shapiro Honored with MSCO Distinguished Researcher Award
Drugs
Dec 19, 2024, 07:24
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy®